Bixiye
2020 February Bulletins
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Natiijooyinka Raadinta
Soo bandhiga 2681 - 2690 ee natiijooyinka 3697
Bixiye
P14-20 BlueRide Transportation – Claims Payment Transition Back to Blue Plus Platform – April 1, 2020
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
P15-20 Change in Requirements for Newborn Precertification Process for Minnesota Health Care Programs
Taariikhda uu dhaqangalayo Barnaamijka: 03, Feb 2020
Bixiye
QP12-20 Reminder for Referring Subscribers to Participating Providers
Taariikhda uu dhaqangalayo Barnaamijka: Jan 22, 2020
Bixiye
QP7-20 Pharmacy Benefit Exclusion for Vyondys 53 (golodirsen)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP1-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) Criteria: Palforzia and Viaskin Peanut (Peanut Allery Oral Immunotherapy)
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP4-20 Minnesota Health Care Programs (MHCP) and Minnesota Senior Health Options (MSHO) Behavioral Health Fax Back Notification Update
Taariikhda uu dhaqangalayo Barnaamijka: Jan 08, 2020
Bixiye
QP16-20 Pharmacy Benefit Exclusion for Padcev TM and Enhertu ®
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP21-20 Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: Baclofen
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020
Bixiye
QP18-20 Pharmacy Benefit Exclusion for Calcipotriene-Betamethasone Dipropionate Suspension 0.005-0.064% (authorized generic (AG) of Taclonex suspension)
Taariikhda uu dhaqangalayo Barnaamijka: 12, Feb 2020